Summary of Erasca (ERAS) FY Conference Call - June 10, 2025 Company Overview - **Company Name**: Erasca (ERAS) - **Mission**: Focused on eradicating RAS-driven cancers, which are mutated in approximately 30% to 50% of all diagnosed cancers annually [3][4] Key Programs - **Current Pipeline**: - **ERAS 15**: A pan RAS molecular glue, recently cleared IND [4][11] - **ERAS 4,001**: A pan KRAS inhibitor, also recently cleared IND [4][11] - **ERAS 12**: A bispecific antibody targeting EGFR, in earlier stages [5] Market Opportunity - **Unmet Need**: Millions of patients diagnosed annually with RAS mutant tumors, with 2.2 million for KRAS and 2.7 million including H and NRAS [7][38] - **Competitive Landscape**: - ERAS 15 has one main competitor, Revolution Medicine's RMC-6,236, but the space is relatively uncrowded due to chemistry and IP challenges [8][10] - The pan KRAS market is more competitive, but ERAS believes their program has a strong profile [8][10] Clinical Development Timeline - **IND Clearances**: Both ERAS 15 and 4,001 received IND clearances in May 2025, ahead of guidance [11][12] - **Phase I Data**: Expected in calendar year 2026 for both programs [12][37] - **Enrollment**: No concerns regarding enrollment due to high unmet need and interest from leading centers [38][39] Preclinical Data Highlights - **Binding Affinity**: ERAS 15 shows 8 to 20 times higher binding affinity to cyclophilin A compared to RMC-6,236 [14] - **In Vitro Potency**: 4 to 5 times greater potency than RMC-6,236 [15] - **Dosing**: Anticipated human dose for ERAS 15 to be about one-tenth of the comparator's dose, potentially leading to better tolerability [18][29] Safety and Efficacy Considerations - **Toxicity Monitoring**: Accumulation of the drug will be monitored, but no major concerns anticipated regarding drug-induced liver injury due to different binding mechanisms [30][31] - **Combination Therapies**: Plans to explore combinations with standard care agents, including cetuximab and PD-1 inhibitors [49][50] Financial Overview - **Licensing Agreements**: - ERAS 15: Upfront payment of $12.5 million, total deal value around $189 million [53] - ERAS 4,001: Upfront payment of $10 million, total deal value around $170 million [55] - **Cash Runway**: Extended guidance to the second half of 2028, providing over three years of cash [67] Strategic Focus - **Reprioritization**: Shifted focus from a pan RAF inhibitor (neparafenib) to RAS programs due to higher unmet needs and potential [59] - **Partnership Opportunities**: Open to finding strategic partners for neparafenib, with no rush to finalize a deal [63] Investor Sentiment - **Positive Feedback**: Investors have responded favorably to the strategic focus on RAS assets and extended cash runway [66][68] Conclusion - **Future Outlook**: Erasca is well-positioned with a strong pipeline and ample cash runway to advance its RAS programs, aiming to address significant unmet needs in oncology [73]

Summary of Eraska Conference Call Company Overview - **Company Name**: Eraska - **Mission**: Focused on erasing cancer, particularly RAS-driven cancers, with a pipeline centered on the RAS MAP kinase pathway [1][2] Key Programs and Pipeline - **Pan RAS Molecule**: ERAS 15, a pan RAS molecular glue, recently cleared for IND [2][4] - **Pan KRAS Inhibitor**: ERAS 4001, a switch to pocket binder, also cleared for IND [2][4] - **Pan RAF Inhibitor**: Naporafenib, currently in phase three for NRAS mutant melanoma, seeking a strategic partner for further development [2][31] - **Biologic**: ERAS 12, a bispecific antibody targeting both active and inactive confirmations of EGFR [3] Clinical Trials - **Trial Design**: Phase one trials for ERAS 15 (AURORAS one) and ERAS 4001 (Borealis one) involve dose escalation followed by monotherapy expansions [6][9] - **Patient Enrollment**: Focus on RAS naive patients for dose escalation [13] - **Expected Dosing Frequency**: ERAS 15 predicted half-life of 24 hours for once daily dosing; ERAS 4001 may require twice daily dosing [11][12] Competitive Landscape - **Market Position**: Eraska is positioned as a strong competitor in the RAS space, with fewer players and a solid preclinical profile compared to competitors like RevMed [39][40] - **Challenges**: Development of new pan RAS molecular glues is complex due to chemistry and limited IP space [40] Efficacy and Safety - **Efficacy Expectations**: ERAS 15 may achieve comparable efficacy at lower doses than RevMed's drug, with a potential one-tenth dose requirement for tumor regression [16][18] - **Safety Profile**: Preclinical data suggest potential safety advantages due to longer tumor residence time [19] Data Disclosure and Future Plans - **Data Guidance**: Expecting to disclose monotherapy data for both ERAS 15 and ERAS 4001 in 2026, with dozens of patients involved [32][50] - **Development Timeline**: Plans to move quickly on dose escalation and explore combination therapies in key indications [34][37] Financial Position - **Cash Reserves**: Approximately $411 million, providing a runway into the second half of 2028, positioning Eraska as one of the best-capitalized companies in the RAS space [49] Strategic Decisions - **Naporafenib Development**: Development paused to extend cash runway and focus on RAS programs [31] - **Partnership Strategy**: Actively seeking a partner for Naporafenib while maintaining focus on advancing RAS programs [46][47] Conclusion - Eraska is strategically positioned in the oncology market with a focused pipeline targeting RAS-driven cancers, strong financial backing, and a clear plan for clinical development and data disclosure. The company aims to leverage its competitive advantages to capture market share in a challenging landscape.

Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026 SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance of an investigational new ...

SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in June 2025 and will also participate in one-on-one investor meetings at each of these conferences. Jefferies Global Healthcare Conference (June 3-5, 2025)Location: New York, NYFo ...

Summary of Erasca (ERAS) 2025 Conference Call Company Overview - **Company**: Erasca (ERAS) - **Event**: Bank of America Health Care Conference, May 14, 2025 - **Speaker**: Jonathan Lim, Chairman, Co-founder, and CEO of Erasca Key Updates and Developments 1. **Clinical Advancements**: - IND clearance of ERAS15, a pan RAS molecular glue, and IND submission of ERAS4001, a pan KRAS small molecule inhibitor, both ahead of schedule [4][21] - ERAS15 is positioned as the lead program, entering Phase 1 dose escalation followed by expansion cohorts [5][21] 2. **Strategic Partnerships**: - Seeking a strategic partner for Naporafenib to enhance development, regulatory, and commercial efforts [4] 3. **Financial Position**: - Cash runway extended from H2 2027 to H2 2028, providing over three years of cash resources [5][22] - More than $400 million on the balance sheet to advance RAS programs [22] Pipeline Focus 1. **ERAS15**: - Potential best-in-class pan RAS molecular glue with strong preclinical activity and low dose requirements for tumor regression [7][8] - High oral bioavailability and expected IP exclusivity through February 2043 [8][9] 2. **ERAS4001**: - KRAS selective inhibitor with good preclinical activity and high oral bioavailability [9][19] - Targets KRAS G12X and G13D mutations effectively [16] 3. **Combination Therapies**: - Promising data on combination treatments with anti-PD-1, showing complete tumor eradication in preclinical models [14][19] Mechanism of Action - ERAS15 binds to cyclophylline A (CYP A) with 8 to 21 fold higher affinity compared to competitors, leading to more potent RAS inhibition [10][11] - Demonstrated superior tumor regression with lower doses compared to existing treatments [11][12] Clinical Development Plan - Focus on major tumor types: colorectal, non-small cell lung cancer, and pancreatic cancer, as well as other tumor types with KRAS mutations [20] - Key milestones include IND filing and Phase I monotherapy data expected in 2026 [21] Additional Insights - ERAS15 shows a favorable pharmacokinetic profile with lower clearance and longer half-life compared to competitors [15][19] - No observed QTc prolongation in cardiovascular studies, indicating a favorable safety profile [19] This summary encapsulates the critical updates and strategic direction of Erasca as discussed during the conference call, highlighting the company's focus on advancing its RAS-targeting therapies and maintaining a strong financial position for future growth.

WASHINGTON, DC 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ______________ Commission File Number: 001-40602 ERASCA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 83-1217027 (State ...

Erasca Reports First Quarter 2025 Business Updates and Financial Results Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $411 million as of March 31, 2025 with cash runway guidance extended to H2 2028 SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinic ...

Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $411 million as of March 31, 2025 with cash runway guidance extended to H2 2028 SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, de ...

Core Viewpoint - Erasca, Inc. is actively participating in the Bank of America Securities 2025 Health Care Conference, highlighting its focus on precision oncology for RAS/MAPK pathway-driven cancers [1]. Company Overview - Erasca, Inc. is a clinical-stage precision oncology company dedicated to discovering, developing, and commercializing therapies specifically for patients with RAS/MAPK pathway-driven cancers [3]. - The company was co-founded by pioneers in precision oncology and RAS targeting, aiming to create novel therapies and combination regimens to effectively shut down the RAS/MAPK pathway [3]. - Erasca has developed one of the most comprehensive pipelines focused on the RAS/MAPK pathway in the industry, supported by a scientific advisory board of leading experts [3]. Event Participation - Management will present at the conference on May 14, 2025, at 2:35 pm Pacific Time and will engage in one-on-one investor meetings [1]. - A live audio webcast of the event will be available on Erasca's website, with an archived replay accessible for 30 days post-event [2].

ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapy First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today pre ...